<page><tag>3</tag><title>Pfizer defends Bextra after new report on risks</title><text>NEW YORK (AFP) - Pfizer dismissed a report on the safety of its pain reliever Bextra, but the new controversy weighed on the stock price of the US pharmaceutical giant.</text></page>